Sara Joanne Sameshima, PA
Physician Assistant · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · Cep America - California
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Sara Joanne Sameshima’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$57,999
Medicare paid this office $57,999 for 389 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 282 | $31,299 | $88 |
| Emergency department visit with high level of medical decision making | 26 | $3,274 | $126 |
| New patient visit (45+ min) | 27 | $2,882 | $107 |
| Short return visit (20+ min) | 32 | $1,660 | $52 |
| Emergency department visit with moderate level of medical decision making | 15 | $1,392 | $93 |
Who their Medicare patients are
389 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 11% · Women 47% · Also on Medicaid 4% · Health risk score 1.09. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 73% · Diabetes 24% · Chronic kidney disease 23% · Coronary heart disease 22% · Cancer 22% · Atrial fibrillation 20% · Depression 13% · Heart failure 12% · COPD 10% · Stroke 8% · Dementia 4%.
The office billed $202,407, Medicare allowed $79,896 and paid $57,999; for 1,391 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 389 | 1,391 | 75 | 1.09 | $202,407 | $57,999 |
| 2023 | 344 | 751 | 74 | 0.94 | $178,071 | $43,551 |
| 2022 | 324 | 376 | 75 | 1.03 | $174,350 | $37,245 |
| 2021 | 388 | 454 | 74 | 1.07 | $195,325 | $46,932 |
| 2020 | 368 | 419 | 75 | 1.12 | $152,569 | $33,587 |
| 2019 | 408 | 493 | 75 | 1.13 | $196,914 | $41,189 |
| 2018 | 143 | 174 | 75 | 1.28 | $62,187 | $14,608 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 145 | $15,107 | $89 |
| Emergency department visit with high level of medical decision making | 39 | $4,624 | $119 |
| New patient visit (45+ min) | 34 | $3,931 | $116 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $3,915 | $98 |
| New patient visit (60+ min) | 18 | $2,593 | $144 |
| Emergency department visit with moderate level of medical decision making | 29 | $2,239 | $77 |
| Short return visit (20+ min) | 34 | $2,033 | $58 |
2022: 7 services
| Return visit (30+ min) | 135 | $13,566 | $93 |
| Emergency department visit with high level of medical decision making | 52 | $7,586 | $140 |
| New patient visit (45+ min) | 51 | $5,651 | $111 |
| Emergency department visit with moderate level of medical decision making | 37 | $3,344 | $88 |
| New patient visit (60+ min) | 12 | $2,052 | $171 |
| Short return visit (20+ min) | 13 | $870 | $67 |
| Emergency department visit with low level of medical decision making | 17 | $857 | $48 |
2021: 6 services
| Return visit (30+ min) | 120 | $14,924 | $102 |
| New patient visit (45+ min) | 83 | $10,386 | $125 |
| Emergency department visit with high level of medical decision making | 61 | $9,331 | $153 |
| Short return visit (20+ min) | 50 | $3,219 | $61 |
| Emergency department visit with moderate level of medical decision making | 32 | $3,099 | $97 |
| Emergency department visit with low level of medical decision making | 32 | $1,734 | $53 |
2020: 6 services
| Return visit (30+ min) | 114 | $10,356 | $78 |
| Emergency department visit with high level of medical decision making | 48 | $6,512 | $136 |
| New patient visit (45+ min) | 50 | $6,412 | $128 |
| Short return visit (20+ min) | 97 | $4,966 | $50 |
| Emergency department visit with moderate level of medical decision making | 31 | $2,808 | $88 |
| Emergency department visit with low level of medical decision making | 24 | $1,092 | $46 |
2019: 6 services
| Return visit (30+ min) | 143 | $13,813 | $84 |
| Emergency department visit with high level of medical decision making | 60 | $7,796 | $126 |
| New patient visit (45+ min) | 43 | $5,512 | $128 |
| Emergency department visit with moderate level of medical decision making | 60 | $5,072 | $85 |
| Short return visit (20+ min) | 70 | $4,370 | $58 |
| Emergency department visit with low level of medical decision making | 42 | $1,907 | $45 |
2018: 5 services
| Emergency department visit with high level of medical decision making | 34 | $4,862 | $143 |
| Return visit (30+ min) | 41 | $3,724 | $85 |
| Emergency department visit with moderate level of medical decision making | 20 | $1,945 | $97 |
| Short return visit (20+ min) | 30 | $1,919 | $58 |
| Emergency department visit with low level of medical decision making | 11 | $565 | $51 |
Drugs they prescribed that Part D paid
$123,860
Pharmacies billed $123,860 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (11 of 618) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
502 generic and 116 brand-name prescriptions · $123,860 in drug cost · 37 antibiotic prescriptions to 30 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sod Sulf-Potass Sulf-Mag Sulf | 161 | $9,921 | $62 |
| Lubiprostone | 15 | $1,883 | $126 |
| Omeprazole | 95 | $1,663 | $18 |
| Famotidine | 59 | $1,250 | $21 |
| Nortriptyline | 32 | $457 | $14 |
See all 6 drugs
| Sod Sulf-Potass Sulf-Mag Sulf | 161 | $9,921 | $62 |
| Lubiprostone | 15 | $1,883 | $126 |
| Omeprazole | 95 | $1,663 | $18 |
| Famotidine | 59 | $1,250 | $21 |
| Nortriptyline | 32 | $457 | $14 |
| Pantoprazole | 20 | $313 | $16 |
Year by year
| 2024 | 618 | 329 | 2% (11) | 19% | $123,860 |
| 2023 | 371 | 233 | None | 26% | $30,126 |
| 2022 | 473 | 255 | 3% (12) | None | $53,584 |
| 2021 | 537 | 310 | 3% (15) | 32% | $36,801 |
| 2020 | 458 | 227 | 5% (22) | 24% | $26,819 |
| 2019 | 405 | 253 | 6% (23) | 33% | $18,284 |
| 2018 | 122 | 92 | 9% (11) | 43% | $12,330 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Clenpiq | 42 | $7,395 | $176 |
| Sod Sulf-Potass Sulf-Mag Sulf | 88 | $6,555 | $74 |
| Famotidine | 35 | $522 | $15 |
| Omeprazole | 45 | $419 | $9 |
| Pantoprazole | 19 | $315 | $17 |
| Ondansetron Odt | 15 | $293 | $20 |
| Nortriptyline | 13 | $100 | $8 |
2022: 9 drugs
| Clenpiq | 75 | $12,657 | $169 |
| Suprep | 30 | $3,458 | $115 |
| Sutab | 13 | $2,157 | $166 |
| Omeprazole | 68 | $900 | $13 |
| Famotidine | 63 | $778 | $12 |
| Ondansetron Odt | 18 | $617 | $34 |
| Pantoprazole | 43 | $453 | $11 |
| Dicyclomine | 19 | $149 | $8 |
| Cephalexin | 11 | $112 | $10 |
2021: 9 drugs
| Suprep | 152 | $16,857 | $111 |
| Omeprazole | 65 | $1,654 | $25 |
| Famotidine | 87 | $1,406 | $16 |
| Lansoprazole | 16 | $772 | $48 |
| Pantoprazole | 26 | $564 | $22 |
| Ondansetron Odt | 20 | $547 | $27 |
| Dicyclomine | 20 | $151 | $8 |
| Cephalexin | 14 | $119 | $9 |
| Hydrocodone-Acetaminophen | 11 | $48 | $4 |
2020: 8 drugs
| Suprep | 88 | $9,252 | $105 |
| Omeprazole | 73 | $1,809 | $25 |
| Famotidine | 84 | $1,135 | $14 |
| Lansoprazole | 23 | $859 | $37 |
| Pantoprazole | 29 | $431 | $15 |
| Nortriptyline | 11 | $114 | $10 |
| Dicyclomine | 14 | $98 | $7 |
| Hydrocodone-Acetaminophen | 14 | $68 | $5 |
2019: 6 drugs
| Suprep | 121 | $12,188 | $101 |
| Lansoprazole | 25 | $1,097 | $44 |
| Omeprazole | 68 | $886 | $13 |
| Famotidine | 37 | $610 | $16 |
| Ranitidine | 11 | $98 | $9 |
| Cephalexin | 12 | $96 | $8 |
2018: 1 drug
| Suprep | 44 | $4,270 | $97 |
Money from drug and device companies
$1,838 in 2025
| 2025 | 11 | 73 | None | $1,838 |
| 2024 | 12 | 62 | None | $1,808 |
| 2023 | 10 | 37 | None | $881 |
| 2022 | 9 | 49 | None | $1,016 |
| 2021 | 8 | 22 | None | $634 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Linzess | $661 | 31 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $491 | 15 payments
|
| Janssen Biotech | Tremfya | $311 | 13 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $108 | 3 payments
|
| QOL Medical | Sucraid | $94 | 4 payments
|
| Aimmune Therapeutics | Zenpep | $55 | 2 payments
|
See all 73 published payments
| Novo Nordisk | Meals · 2025-12-15 | Wegovy | $32 |
| Madrigal Pharmaceuticals | Meals · 2025-12-09 | Rezdiffra | $29 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-01 | Xifaxan | $70 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-01 | Xifaxan | $16 |
| QOL Medical | Meals · 2025-11-17 | Sucraid | $29 |
| Janssen Biotech | Meals · 2025-11-12 | Tremfya | $20 |
| Madrigal Pharmaceuticals | Meals · 2025-11-04 | Rezdiffra | $7 |
| Aimmune Therapeutics | Meals · 2025-11-03 | Zenpep | $26 |
| Lilly USA | Meals · 2025-10-30 | None | $22 |
| Janssen Biotech | Meals · 2025-10-28 | Tremfya | $20 |
| Aimmune Therapeutics | Meals · 2025-10-23 | Zenpep | $29 |
| Abbvie | Meals · 2025-10-22 | Linzess | $18 |
| Madrigal Pharmaceuticals | Meals · 2025-10-21 | Rezdiffra | $12 |
| Abbvie | Meals · 2025-10-14 | Linzess | $31 |
| Abbvie | Meals · 2025-10-10 | Linzess | $28 |
| Madrigal Pharmaceuticals | Meals · 2025-10-07 | Rezdiffra | $37 |
| Abbvie | Meals · 2025-10-01 | Rinvoq | $26 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-22 | Iqirvo | $18 |
| QOL Medical | Meals · 2025-09-18 | Sucraid | $23 |
| Abbvie | Meals · 2025-09-10 | Linzess | $18 |
| Madrigal Pharmaceuticals | Meals · 2025-09-09 | Rezdiffra | $41 |
| Janssen Biotech | Meals · 2025-09-08 | Tremfya | $33 |
| Abbvie | Meals · 2025-09-05 | Creon | $24 |
| Abbvie | Meals · 2025-08-28 | Linzess | $21 |
| Janssen Biotech | Meals · 2025-08-27 | Tremfya | $24 |
| Janssen Biotech | Meals · 2025-08-26 | Tremfya | $7 |
| Abbvie | Meals · 2025-08-26 | Rinvoq | $29 |
| Abbvie | Meals · 2025-08-20 | Rinvoq | $28 |
| QOL Medical | Meals · 2025-08-18 | Sucraid | $18 |
| Madrigal Pharmaceuticals | Meals · 2025-08-12 | Rezdiffra | $22 |
| Abbvie | Meals · 2025-07-22 | Linzess | $25 |
| Abbvie | Meals · 2025-07-18 | Linzess | $17 |
| QOL Medical | Meals · 2025-07-10 | Sucraid | $24 |
| Madrigal Pharmaceuticals | Meals · 2025-07-08 | Rezdiffra | $31 |
| Abbvie | Meals · 2025-07-01 | Creon | $15 |
| Abbvie | Meals · 2025-06-11 | Linzess | $30 |
| Abbvie | Meals · 2025-06-10 | Linzess | $12 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-10 | Xifaxan | $23 |
| Janssen Biotech | Meals · 2025-06-09 | Tremfya | $23 |
| Abbvie | Meals · 2025-06-05 | Rinvoq | $29 |
| Madrigal Pharmaceuticals | Meals · 2025-06-03 | Rezdiffra | $28 |
| Janssen Biotech | Meals · 2025-05-28 | Tremfya | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-15 | Entyvio | $18 |
| Janssen Biotech | Meals · 2025-05-09 | Tremfya | $5 |
| Abbvie | Meals · 2025-05-09 | Linzess | $23 |
| Madrigal Pharmaceuticals | Meals · 2025-05-08 | Rezdiffra | $11 |
| Madrigal Pharmaceuticals | Meals · 2025-05-06 | Rezdiffra | $34 |
| Abbvie | Meals · 2025-04-25 | Creon | $25 |
| Abbvie | Meals · 2025-04-17 | Skyrizi | $6 |
| Abbvie | Meals · 2025-04-16 | Rinvoq | $21 |
| Janssen Biotech | Meals · 2025-04-10 | Tremfya | $23 |
| Janssen Biotech | Meals · 2025-04-09 | Tremfya | $28 |
| Madrigal Pharmaceuticals | Meals · 2025-04-08 | Rezdiffra | $37 |
| Ardelyx | Meals · 2025-04-03 | Ibsrela | $28 |
| Abbvie | Meals · 2025-04-01 | Creon | $33 |
| Abbvie | Meals · 2025-03-20 | Skyrizi | $27 |
| Abbvie | Meals · 2025-03-13 | Skyrizi | $25 |
| Abbvie | Meals · 2025-03-12 | Linzess | $20 |
| Janssen Biotech | Meals · 2025-03-06 | Tremfya | $84 |
| Madrigal Pharmaceuticals | Meals · 2025-03-04 | Rezdiffra | $35 |
| Abbvie | Meals · 2025-02-28 | Creon | $29 |
| Abbvie | Meals · 2025-02-18 | Creon | $14 |
| Abbvie | Meals · 2025-02-18 | Creon | $10 |
| Abbvie | Meals · 2025-02-15 | Linzess | $4 |
| Janssen Biotech | Meals · 2025-02-11 | Tremfya | $3 |
| Janssen Biotech | Meals · 2025-02-11 | Tremfya | $15 |
| Madrigal Pharmaceuticals | Meals · 2025-02-11 | Rezdiffra | $6 |
| Madrigal Pharmaceuticals | Meals · 2025-02-05 | Rezdiffra | $33 |
| Abbvie | Meals · 2025-02-03 | Rinvoq | $8 |
| Abbvie | Meals · 2025-01-23 | Skyrizi | $8 |
| Abbvie | Meals · 2025-01-23 | Skyrizi | $28 |
| Abbvie | Meals · 2025-01-22 | Rinvoq | $29 |
| Madrigal Pharmaceuticals | Meals · 2025-01-21 | Rezdiffra | $127 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,808
| Abbvie | Rinvoq | $630 | 22 payments
|
| Janssen Biotech | Stelara | $383 | 10 payments
|
| Lilly USA | Omvoh | $232 | 10 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $218 | 6 payments
|
| QOL Medical | Sucraid | $95 | 4 payments
|
| Phathom Pharmaceuticals | Voquezna | $86 | 3 payments
|
| Celltrion USA | Vegzelma | $45 | 2 payments
|
| Ironwood Pharmaceuticals | Linzess | $31 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $24 | 1 payment
|
| Pfizer | Xeljanz | $22 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $22 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $20 | 1 payment
|
2023: $881
| Abbvie | Viberzi | $335 | 13 payments
|
| Janssen Biotech | Stelara | $254 | 11 payments
|
| QOL Medical | Sucraid | $80 | 4 payments
|
| Fresenius Kabi USA | Idacio | $66 | 2 payments
|
| Gilead Sciences | None | $49 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Andexxa | $25 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $21 | 1 payment
|
| Celltrion USA | Yuflyma | $20 | 1 payment
|
| Braintree Laboratories | Suflave | $16 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $14 | 1 payment
|
2022: $1,016
| Abbvie | Humira | $537 | 30 payments
|
| Janssen Biotech | Remicade | $188 | 5 payments
|
| Braintree Laboratories | Sutab | $87 | 4 payments
|
| Intercept Pharmaceuticals | Ocaliva | $87 | 4 payments
|
| Gilead Sciences | None | $41 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $23 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $19 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $18 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $18 | 1 payment
|
2021: $634
| AbbVie | Humira | $241 | 11 payments
|
| Janssen Biotech | Remicade | $150 | 3 payments
|
| Gilead Sciences | Vemlidy | $100 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $43 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $33 | 2 payments
|
| Ironwood Pharmaceuticals | Linzess | $27 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720576473
- Licence
- CA PA55622
- Group
- Sutter Bay Medical Foundation · Cep America - California
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- Po Box 276950, Sacramento, CA, 95827
- NPI first listed
- 2018-04-27
- NPI last updated
- 2024-12-03
- NPI record certified
- 2024-12-03
This is when the NPI record was last certified, not a medical board exam.